for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Charles River Laboratories Intl. Inc

CRL.N

Latest Trade

417.71USD

Change

-14.76(-3.41%)

Volume

114,941

Today's Range

413.02

 - 

426.49

52 Week Range

219.11

 - 

460.21

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
432.47
Open
426.49
Volume
114,941
3M AVG Volume
6.51
Today's High
426.49
Today's Low
413.02
52 Week High
460.21
52 Week Low
219.11
Shares Out (MIL)
50.40
Market Cap (MIL)
21,795.03
Forward P/E
44.43
Dividend (Yield %)
--

Next Event

Q3 2021 Charles River Laboratories International Inc Earnings Release

Latest Developments

More

Charles River Laboratories Posts Q2 Gaap Earnings Per Share $1.72

Charles River Laboratories To Acquire Vigene Biosciences For Purchase Price Of $292.5 Mln In Cash

Charles River Laboratories International Inc Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Charles River Laboratories Intl. Inc

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices, and therapies. The Company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the Research Models, Research Model Services, and Research Products businesses. The DSA segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions, and Avian Vaccine Services.

Industry

Biotechnology & Drugs

Contact Info

251 Ballardvale St

WILMINGTON, MA

01887-1096

United States

+1.781.2226000

https://www.criver.com/

Executive Leadership

James C. Foster

Chairman of the Board, President, Chief Executive Officer

David Ross Smith

Chief Financial Officer, Corporate Executive Vice President

William D. Barbo

Corporate Executive Vice President and Chief Commercial Officer

Birgit Girshick

Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian

Joseph W. LaPlume

Corporate Executive Vice President, Corporate Development and Strategy

Key Stats

1.69 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

2.3K

2019

2.6K

2020

2.9K

2021(E)

3.6K
EPS (USD)

2018

6.030

2019

6.730

2020

8.130

2021(E)

10.316
Price To Earnings (TTM)
55.82
Price To Sales (TTM)
6.66
Price To Book (MRQ)
9.40
Price To Cash Flow (TTM)
33.49
Total Debt To Equity (MRQ)
117.76
LT Debt To Equity (MRQ)
117.63
Return on Investment (TTM)
7.83
Return on Equity (TTM)
6.70

Latest News

Latest News

S.C. horseshoe crab harvest for pharma can proceed - 4th Circuit

A federal appeals court has allowed the harvesting in a South Carolina national refuge of horseshoe crabs whose blood is used to test the safety of vaccines, a Monday court filing shows.

BRIEF-Charles River Laboratories Increases Size Of Board To 12

Charles River Laboratories International Inc:

Blue-blooded crabs at heart of pharma dispute on drug testing

If you've received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you've benefited from a vast bloodletting of horseshoe crabs.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up